Evidence map›Paper›PMID 31441218›Full record

ArticleVeterinary ophthalmology2020

Horses with equine recurrent uveitis have an activated CD4+ T-cell phenotype that can be modulated by mesenchymal stem cells in vitro.

Laurel K Saldinger, Seldy G Nelson, Rebecca R Bellone, Mary Lassaline, Maura Mack, Naomi J Walker, Dori L Borjesson

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Veterinary ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 35 citations in OpenAlex.

  1. Cell and Gene Therapy in Equine Ocular Disease.Veterinary ophthalmology · 2026
    Review
  2. Mesenchymal Stem Cells in Veterinary Medicine-Still Untapped Potential.Animals : an open access journal from MDPI · 2025
    Review
  3. Review
  4. Enhanced ROS Production and Mitochondrial Metabolic Shifts in CD4International journal of molecular sciences · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Laurel K SaldingerDepartment of Pathology, Microbiology and Immunology, Veterinary Institute for Regenerative Cures, School of Veterinary Medicine, University of California, Davis, California.ORCID https://orcid.org/0000-0001-9941-581X
Seldy G NelsonDepartment of Pathology, Microbiology and Immunology, Veterinary Institute for Regenerative Cures, School of Veterinary Medicine, University of California, Davis, California.
Rebecca R BelloneDepartment of Population Health and Reproduction, Veterinary Genetics Laboratory, School of Veterinary Medicine, University of California, Davis, California.
Mary LassalineDepartment of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, California.
Maura MackDepartment of Population Health and Reproduction, Veterinary Genetics Laboratory, School of Veterinary Medicine, University of California, Davis, California.
Naomi J WalkerDepartment of Pathology, Microbiology and Immunology, Veterinary Institute for Regenerative Cures, School of Veterinary Medicine, University of California, Davis, California.
Dori L BorjessonDepartment of Pathology, Microbiology and Immunology, Veterinary Institute for Regenerative Cures, School of Veterinary Medicine, University of California, Davis, California.
California Institute for Regenerative Medicine · USUniversity of California, Davis · US

Funding

Students Training in Advanced Research (STAR) ProgramT35OD010956 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DANIKA L BANNASCH · 2012 to 2026
$1.6M
Center for Equine Health at UC DavisNIH Clinical Center T35 OD010956-19NIH HHS T35 OD010956
6 · The paper itself

Abstract

Equine recurrent uveitis (ERU) is an immune-mediated disease causing repeated or persistent inflammatory episodes which can lead to blindness. Currently, there is no cure for horses with this disease. Mesenchymal stem cells (MSCs) are effective at reducing immune cell activation in vitro in many species, making them a potential therapeutic option for ERU. The objectives of this study were to define the lymphocyte phenotype of horses with ERU and to determine how MSCs alter T-cell phenotype in vitro. Whole blood was taken from 7 horses with ERU and 10 healthy horses and peripheral blood mononuclear cells were isolated. The markers CD21, CD3, CD4, and CD8 were used to identify lymphocyte subsets while CD25, CD62L, Foxp3, IFNγ, and IL10 were used to identify T-cell phenotype. Adipose-derived MSCs were expanded, irradiated (to control proliferation), and incubated with CD4

Indexed as

AnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCells, CulturedCoculture TechniquesGene Expression RegulationHorse DiseasesHorsesInterferon-gammaInterleukin-2 Receptor alpha SubunitL-SelectinMesenchymal Stem CellsUveitisInterferon-gammaInterleukin-2 Receptor alpha SubunitL-Selectinactivated CD4+ T-cellsequine recurrent uveitisimmunomodulationmesenchymal stem cells

Identifiers

PMID31441218
PMCPMC6980227
OpenAlexW2969949664

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.